
Preclinical data suggests functional cure for HBV
Epigenome editing company Tune Therapeutics has showcased new data at the American Association for the Study of Liver Diseases (AASLD) conference, in support of its drive to develop a lasting, functional cure for chronic Hepatitis B Virus (HBV). Tune presented its lead HBV programme at the 2023 iteration of the… Read More
